Literature DB >> 25720398

NK Cells are Activated in Amnestic Mild Cognitive Impairment but not in Mild Alzheimer's Disease Patients.

Aurélie Le Page1, Karine Bourgade1, Julie Lamoureux2, Eric Frost3, Graham Pawelec4, Anis Larbi5, Jacek M Witkowski6, Gilles Dupuis7, Tamás Fülöp1.   

Abstract

Alzheimerś disease (AD) is a progressive irreversible neurological brain disorder characterized by accumulation of amyloid-β, amyloid plaques, and neurofibrillary tangles. Inflammation and immune alterations have been linked to AD, suggesting that the peripheral immune system plays a role during the asymptomatic period of AD. NK cells participate in innate immune surveillance against intracellular pathogens and malignancy but their role in AD remains controversial. We have investigated changes in peripheral NK cell phenotypes and functions in amnestic mild cognitive impairment (aMCI, n = 10), patients with mild AD (mAD, n = 11), and healthy elderly controls (n = 10). Patients selected according to NINCDS-ADRDA criteria were classified using neuropsychological assessment tests. Phenotype analysis revealed differences in expression of CD16 (increased in mAD), NKG2A (decreased in aMCI), and TLR2 and TLR9 (both decreased in mAD). Functional assays revealed that NK cell killing activity and degranulation (CD107 expression) were unchanged in the three groups. In contrast, expression of the CD95 receptor was increased in aMCI and mAD. Granzyme B expression and cytokine production (TNFα, IFNγ) were increased in aMCI but not in mAD. CCL19- but not CCL21-dependent chemotaxis was decreased in aMCI and mAD, despite the fact that CCR7 expression was increased in aMCI. Our data suggest that the number of alterations observed in peripheral NK cells in aMCI represent an activation state compared to mAD patients and that may reflect an active immune response against a still to be defined aggression.

Entities:  

Keywords:  Alzheimer’s disease; amnestic mild cognitive impairment; cell cytotoxicity; chemotaxis; natural killer cells; phenotyping; toll-like receptors

Mesh:

Substances:

Year:  2015        PMID: 25720398     DOI: 10.3233/JAD-143054

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  18 in total

Review 1.  Age has a role in driving host immunopathological response to alphavirus infection.

Authors:  Yi-Hao Chan; Lisa F P Ng
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

2.  Immune cells lacking Y chromosome show dysregulation of autosomal gene expression.

Authors:  Hanna Davies; Edyta Rychlicka-Buniowska; Jonas Mattisson; Behrooz Torabi Moghadam; Jan P Dumanski; Jonatan Halvardson; Noemi Nagy; Kazimierz Węglarczyk; Karolina Bukowska-Strakova; Marcus Danielsson; Paweł Olszewski; Arkadiusz Piotrowski; Erin Oerton; Aleksandra Ambicka; Marcin Przewoźnik; Łukasz Bełch; Tomasz Grodzicki; Piotr L Chłosta; Stefan Imreh; Vilmantas Giedraitis; Lena Kilander; Jessica Nordlund; Adam Ameur; Ulf Gyllensten; Åsa Johansson; Alicja Józkowicz; Maciej Siedlar; Alicja Klich-Rączka; Janusz Jaszczyński; Stefan Enroth; Jarosław Baran; Martin Ingelsson; John R B Perry; Janusz Ryś; Lars A Forsberg
Journal:  Cell Mol Life Sci       Date:  2021-04-10       Impact factor: 9.261

3.  Linkage of Alzheimer disease families with Puerto Rican ancestry identifies a chromosome 9 locus.

Authors:  Farid Rajabli; Briseida E Feliciano-Astacio; Holly N Cukier; Liyong Wang; Anthony J Griswold; Kara L Hamilton-Nelson; Larry D Adams; Vanessa C Rodriguez; Pedro R Mena; Sergio Tejada; Katrina Celis; Patrice L Whitehead; Derek J Van Booven; Natalia K Hofmann; Parker L Bussies; Michael Prough; Angel Chinea; Nereida I Feliciano; Badri N Vardarajan; Christiane Reitz; Joseph H Lee; Martin J Prince; Ivonne Z Jimenez; Richard P Mayeux; Heriberto Acosta; Clifton L Dalgard; Jonathan L Haines; Jeffery M Vance; Michael L Cuccaro; Gary W Beecham; Margaret A Pericak-Vance
Journal:  Neurobiol Aging       Date:  2021-02-28       Impact factor: 5.133

4.  Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnestic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients.

Authors:  Aurélie Le Page; Hugo Garneau; Gilles Dupuis; Eric H Frost; Anis Larbi; Jacek M Witkowski; Graham Pawelec; Tamàs Fülöp
Journal:  Front Immunol       Date:  2017-07-07       Impact factor: 7.561

5.  Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment.

Authors:  Ann M Stowe; Sara J Ireland; Sterling B Ortega; Ding Chen; Ryan M Huebinger; Takashi Tarumi; Thomas S Harris; C Munro Cullum; Roger Rosenberg; Nancy L Monson; Rong Zhang
Journal:  J Neuroinflammation       Date:  2017-07-27       Impact factor: 8.322

Review 6.  Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer's Disease.

Authors:  Corona Solana; Raquel Tarazona; Rafael Solana
Journal:  Int J Alzheimers Dis       Date:  2018-11-01

Review 7.  A Perspective on Roles Played by Immunosenescence in the Pathobiology of Alzheimer's Disease.

Authors:  Yan Zhao; Jun-Kun Zhan; Youshuo Liu
Journal:  Aging Dis       Date:  2020-12-01       Impact factor: 6.745

8.  Impairment of Several Immune Functions and Redox State in Blood Cells of Alzheimer's Disease Patients. Relevant Role of Neutrophils in Oxidative Stress.

Authors:  Carmen Vida; Irene Martinez de Toda; Antonio Garrido; Eva Carro; José Antonio Molina; Mónica De la Fuente
Journal:  Front Immunol       Date:  2018-01-11       Impact factor: 7.561

Review 9.  Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer's Disease?

Authors:  Tamas Fulop; Jacek M Witkowski; Karine Bourgade; Abdelouahed Khalil; Echarki Zerif; Anis Larbi; Katsuiku Hirokawa; Graham Pawelec; Christian Bocti; Guy Lacombe; Gilles Dupuis; Eric H Frost
Journal:  Front Aging Neurosci       Date:  2018-07-24       Impact factor: 5.750

Review 10.  Role of Peripheral Immune Cells-Mediated Inflammation on the Process of Neurodegenerative Diseases.

Authors:  Qiuyu Yang; Guoqing Wang; Feng Zhang
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.